Aug 2026 $9 M No. 13 $2 to $10 million 14
Aspyrian Therapeutics, Inc.: Raise no. 13, Aug 2026 × Investors in this round 14 investors had bought by the notice of Oct 6, 2026: 14 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $9 M of $9 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Abhijit Bhatia · Executive Officer Amy Thorne · Executive Officer Anthony Manibusan · Executive Officer Hassan Danesi · Executive Officer Hiroyuki Kodama · Executive Officer Louise Chang · Executive Officer Maeda Minami · Executive Officer Suzane San · Executive Officer Tiffany Piecewicz · Executive Officer Toshiaki Suzuki · Executive Officer Christophe Weber · Director David Chao · Director Eiichi Kaga · Director Hiroshi Mikitani · Director Hiroshi Mori · Director Ken Takeshita · Director Mazen Darwazeh · Director Miguel Garcia-Guzman · Director Nitin Nohria · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Tiffany Piecewicz, Secretary. Source: SEC Form D, newest notice filed Oct 6, 2026. Read the notice at the SEC .
options SEC Jul 2025 $112 M No. 12 $50 to $250 million 26
Aspyrian Therapeutics, Inc.: Raise no. 12, Jul 2025 × Investors in this round 26 investors had bought by the notice of Apr 13, 2026: 26 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $112 M of $117 M offered; $5 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Abhijit Bhatia · Executive Officer Carlos Garcia · Executive Officer Hiroshi Mikitani · Executive Officer, Director Hiroyuki Kodama · Executive Officer Maeda Minami · Executive Officer Suzane San · Executive Officer Tiffany Piecewicz · Executive Officer Toshiaki Suzuki · Executive Officer David Chao · Director Eiichi Kaga · Director Hiroshi Mori · Director Kentaro Hyakuno · Director Mazen Darwazah · Director Miguel Garcia-Guzman · Director Nitin Nohria · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Tiffany Piecewicz, Secretary. Source: SEC Form D, newest notice filed Apr 13, 2026. Read the notice at the SEC .
equity SEC Dec 2024 $2 M No. 11 Under $2 million 14
Aspyrian Therapeutics, Inc.: Raise no. 11, Dec 2024 × Investors in this round 14 investors had bought by the notice of May 7, 2025: 14 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Abhijit Bhatia · Executive Officer Carlos Garcia · Executive Officer Hiroshi Mikitani · Executive Officer, Director Minami Maeda · Executive Officer Suzane San · Executive Officer Tiffany Piecewicz · Executive Officer Toshiaki Suzuki · Executive Officer David Chao · Director Eiichi Kaga · Director Hiroshi Mori · Director Kentaro Hyakuno · Director Mazen Darwazah · Director Miguel Garcia-Guzman · Director Nitin Nohria · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Tiffany Piecewicz, Secretary. Source: SEC Form D and 1 amendment, newest notice filed May 7, 2025. Read the notice at the SEC .
options SEC Mar 2024 $4 M No. 10 $2 to $10 million 15
Aspyrian Therapeutics, Inc.: Raise no. 10, Mar 2024 × Investors in this round 15 investors had bought by the notice of Mar 28, 2024: 15 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Abhijit Bhatia · Executive Officer Agatha Martindale · Executive Officer Carlos Garcia · Executive Officer Hiroshi Mikitani · Executive Officer, Director Minami Maeda · Executive Officer Suzane San · Executive Officer Takashi Toraishi · Executive Officer, Director Tiffany Piecewicz · Executive Officer Toshiaki Suzuki · Executive Officer David Chao · Director Hiroshi Mori · Director Hiroshi Takasawa · Director Kentaro Hyakuno · Director Mazen Darwazah · Director Miguel Garcia-Guzman · Director Nitin Nohria · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Tiffany Piecewicz, Secretary. Source: SEC Form D, newest notice filed Mar 28, 2024. Read the notice at the SEC .
options SEC Aug 2023 $105 M No. 9 $50 to $250 million 15
Aspyrian Therapeutics, Inc.: Raise no. 9, Aug 2023 × Investors in this round 15 investors had bought by the notice of Sep 1, 2023: 15 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $105 M of $124 M offered; $19 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Abhijit Bhatia · Executive Officer Carlos Garcia · Executive Officer Hiroshi Mikitani · Executive Officer, Director Takashi Toraishi · Executive Officer, Director Tiffany Piecewicz · Executive Officer David Chao · Director Hiroshi Mori · Director Hiroshi Takasawa · Director Kentaro Hyakuno · Director Mazen Darwazeh · Director Miguel Garcia-Guzman · Director Nitin Nohria · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Includes shares of capital stock issued pursuant to conversion of convertible notes in the amount of $73,689,146.18.”Signed by Tiffany Piecewicz, Secretary. Source: SEC Form D, newest notice filed Sep 1, 2023. Read the notice at the SEC .
equity SEC Jun 2022 $2 M No. 8 $2 to $10 million 20
Aspyrian Therapeutics, Inc.: Raise no. 8, Jun 2022 × Investors in this round 20 investors had bought by the notice of Oct 4, 2023: 20 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Abhijit Bhatia · Executive Officer Carlos Garcia · Executive Officer Hiroshi Mikitani · Executive Officer, Director Takashi Toraishi · Executive Officer, Director Tiffany Piecewicz · Executive Officer Toshiaki Suzuki · Executive Officer David Chao · Director Hiroshi Mori · Director Hiroshi Takasawa · Director Kentaro Hyakuno · Director Mazen Darwazeh · Director Miguel Garcia-Guzman · Director Nitin Nohria · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Tiffany Piecewicz, Secretary. Source: SEC Form D and 1 amendment, newest notice filed Oct 4, 2023. Read the notice at the SEC .
options SEC Jul 2021 $166 M No. 7 $50 to $250 million 10
Aspyrian Therapeutics, Inc.: Raise no. 7, Jul 2021 × Investors in this round 10 investors had bought by the notice of Jul 29, 2021: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $166 M of $291 M offered; $125 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $3,000,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Ann McGuire · Executive Officer Carlos Garcia · Executive Officer Hiroshi Mikitani · Executive Officer, Director Miguel Garcia-Guzman · Executive Officer, Director Takashi Toraishi · Executive Officer, Director David Chao · Director Hiroshi Mori · Director Hiroshi Takasawa · Director Kentaro Hyakuno · Director Nitin Nohria · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round TAP Securities LLC (CRD 151593) · New York, New York Sold in AZ, CA, CO, CT, DC, FL, IL, IN, LA, MA, MD, MO, NC, NJ, NY, OR, PA, SC, TX, UT, VA, WA, and outside the US Momentum Capital Markets, LLC (CRD 300288) · San Francisco, California Sold in CA, and outside the US Signed by Brenton Keath, Chief Financial Officer and Chief Operating Officer. Source: SEC Form D, newest notice filed Jul 29, 2021. Read the notice at the SEC .
equity SEC Dec 2020 $15 M Issued in a merger or acquisition $10 to $50 million 1
Aspyrian Therapeutics, Inc.: Private sale, Dec 2020 × Investors in this round 1 investor had bought by the notice of Jan 14, 2021: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $15 M of $15 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Brenton Keath · Executive Officer Carlos Garcia · Executive Officer Hiroshi Mikitani · Executive Officer, Director Miguel Garcia-Guzman · Executive Officer, Director Takashi Toraishi · Executive Officer, Director David Chao · Director Hiroshi Mori · Director Kentaro Hyakuno · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Brenton Keath, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 14, 2021. Read the notice at the SEC .
equity SEC Jul 2019 $100 M No. 6 $50 to $250 million 1
Aspyrian Therapeutics, Inc.: Raise no. 6, Jul 2019 × Investors in this round 1 investor had bought by the notice of Aug 7, 2019: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $100 M of $100 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Carlos Garcia · Executive Officer Hiroshi Mikitani · Executive Officer, Director Miguel Garcia-Guzman · Executive Officer, Director Takashi Toraishi · Executive Officer, Director David Chao · Director Hiroshi Mori · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Takashi Toraishi, President. Source: SEC Form D, newest notice filed Aug 7, 2019. Read the notice at the SEC .
equity SEC Aug 2018 $150 M No. 5 $50 to $250 million 4
Aspyrian Therapeutics, Inc.: Raise no. 5, Aug 2018 × Investors in this round 4 investors had bought by the notice of Nov 7, 2018: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $150 M of $350 M offered; $200 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Carlos Garcia · Executive Officer Hiroshi Mikitani · Executive Officer, Director Merrill Biel · Executive Officer, Director Miguel Garcia-Guzman · Executive Officer, Director Takashi Toraishi · Executive Officer Hiroshi Mori · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Hiroshi Mikitani, President. Source: SEC Form D and 2 amendments, newest notice filed Nov 7, 2018. Read the notice at the SEC .
equity SEC Jul 2017 $15 M No. 4 $10 to $50 million 45
Aspyrian Therapeutics, Inc.: Raise no. 4, Jul 2017 × Investors in this round 45 investors had bought by the notice of Jul 21, 2017: 45 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $15 M of $19 M offered; $4 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Merrill Biel · Executive Officer, Director Miguel Garcia-Guzman · Executive Officer, Director Hiroshi Mikitani · Director Hiroshi Mori · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Miguel Garcia-Guzman, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 21, 2017. Read the notice at the SEC .
equity SEC Feb 2016 $55 M No. 3 $50 to $250 million 8
Aspyrian Therapeutics, Inc.: Raise no. 3, Feb 2016 × Investors in this round 8 investors had bought by the notice of Oct 5, 2016: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $55 M of $56 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Merrill Biel · Executive Officer, Director Miguel Garcia-Guzman · Executive Officer, Director Hiroshi Mikitani · Director Hiroshi Mori · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Miguel Garcia-Guzman, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 5, 2016. Read the notice at the SEC .
equity SEC Jul 2015 $4 M No. 2 $2 to $10 million 3
Aspyrian Therapeutics, Inc.: Raise no. 2, Jul 2015 × Investors in this round 3 investors had bought by the notice of Jul 30, 2015: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Merrill Biel · Executive Officer, Director Miguel Garcia-Guzman · Executive Officer, Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Miguel Garcia-Guzman, President. Source: SEC Form D, newest notice filed Jul 30, 2015. Read the notice at the SEC .
equity SEC Dec 2014 $8 M No. 1 $2 to $10 million 8
Aspyrian Therapeutics, Inc.: Raise no. 1, Dec 2014 × Investors in this round 8 investors had bought by the notice of Jan 23, 2015: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $8 M of $8 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Miguel Garcia-Guzman · Executive Officer, Director Scott Salka · Executive Officer, Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Total amount sold includes $6,480,000 of securities issued upon conversion of the principal and interest outstanding under a convertible promissory note. Also includes $176 of Common Stock sold pursuant to a Common Stock Purchase Agreement.”Signed by Scott Salka, Ceo. Source: SEC Form D, newest notice filed Jan 23, 2015. Read the notice at the SEC .
equity, options SEC